Galectin Therapeutics (GALT) Income from Continuing Operations (2010 - 2026)
Galectin Therapeutics' quarterly Income from Continuing Operations came in at 6029000.0 in Q1 2026, up 37.24% year-on-year from 4393125.54 in Q1 2025, and down 14.21% quarter-over-quarter from 5279000.0 in Q4 2025.
Galectin Therapeutics has reported Income from Continuing Operations for 17 years, with the latest figure at 6029000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 37.24% year-over-year to 6029000.0; the trailing twelve-month figure through Mar 2026 stood at 23712000.0 (up 49.14% YoY), and the FY2025 full-year result was 27288000.0, up 42.71% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 6029000.0, down from 5279000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 5279000.0 in Q4 2025, with the low at 14069000.0 in Q4 2024.
- Average Income from Continuing Operations over 5 years is 9465941.18, with a median of 9939000.0 recorded in 2023.
- Year-over-year, Income from Continuing Operations plunged 60.32% in 2022 and soared 62.48% in 2025.
- Tracing GALT's Income from Continuing Operations over 5 years: stood at 10911000.0 in 2022, then advanced by 5.29% to 10334000.0 in 2023, then sank by 36.14% to 14069000.0 in 2024, then soared by 62.48% to 5279000.0 in 2025, then declined by 14.21% to 6029000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 6029000.0 (Q1 2026), 5279000.0 (Q4 2025), and 5979000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | -6.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.03 Mn |
| Dec 31, 2025 | -5.28 Mn |
| Sep 30, 2025 | -5.98 Mn |
| Jun 30, 2025 | -6.43 Mn |
| Mar 31, 2025 | -9.61 Mn |
| Dec 31, 2024 | -14.07 Mn |
| Sep 30, 2024 | -10.47 Mn |
| Jun 30, 2024 | -12.48 Mn |
| Mar 31, 2024 | -10.62 Mn |
| Dec 31, 2023 | -10.33 Mn |
| Sep 30, 2023 | -9.94 Mn |
| Jun 30, 2023 | -9.60 Mn |
| Mar 31, 2023 | -10.76 Mn |
| Dec 31, 2022 | -10.91 Mn |
| Sep 30, 2022 | -8.37 Mn |
| Jun 30, 2022 | -9.89 Mn |
| Mar 31, 2022 | -10.16 Mn |
| Dec 31, 2021 | -7.70 Mn |
| Sep 30, 2021 | -8.25 Mn |
| Jun 30, 2021 | -8.28 Mn |
| Mar 31, 2021 | -6.34 Mn |
| Dec 31, 2020 | -7.85 Mn |
| Sep 30, 2020 | -5.94 Mn |
| Jun 30, 2020 | -6.11 Mn |
| Mar 31, 2020 | -3.56 Mn |
| Dec 31, 2019 | -5.14 Mn |
| Sep 30, 2019 | -2.78 Mn |
| Jun 30, 2019 | -3.00 Mn |
| Mar 31, 2019 | -2.38 Mn |
| Dec 31, 2018 | -3.05 Mn |
| Sep 30, 2018 | -2.75 Mn |
| Jun 30, 2018 | -3.84 Mn |
| Mar 31, 2018 | -4.26 Mn |
| Dec 31, 2017 | -2.37 Mn |
| Sep 30, 2017 | -4.41 Mn |
| Jun 30, 2017 | -4.51 Mn |
| Mar 31, 2017 | -4.94 Mn |
| Dec 31, 2016 | -4.59 Mn |
| Sep 30, 2016 | -4.53 Mn |
| Jun 30, 2016 | -5.52 Mn |
| Mar 31, 2016 | -6.80 Mn |
| Dec 31, 2015 | -4.67 Mn |
| Sep 30, 2015 | -5.89 Mn |
| Jun 30, 2015 | -4.64 Mn |
| Mar 31, 2015 | -4.83 Mn |
| Dec 31, 2014 | -3.72 Mn |
| Sep 30, 2014 | -3.47 Mn |
| Jun 30, 2014 | -3.36 Mn |
| Mar 31, 2014 | -4.84 Mn |
| Dec 31, 2013 | -2.80 Mn |
| Sep 30, 2013 | -3.54 Mn |
| Jun 30, 2013 | -2.54 Mn |
| Mar 31, 2013 | -3.20 Mn |
| Dec 31, 2012 | -2.38 Mn |
| Sep 30, 2012 | -2.89 Mn |
| Jun 30, 2012 | -2.66 Mn |
| Mar 31, 2012 | -1.95 Mn |
| Dec 31, 2011 | -3.37 Mn |
| Sep 30, 2011 | -2.03 Mn |
| Jun 30, 2011 | -2.99 Mn |
| Mar 31, 2011 | -2.01 Mn |
| Dec 31, 2010 | -1.29 Mn |
| Sep 30, 2010 | -1.21 Mn |
| Jun 30, 2010 | -1.35 Mn |